BMX Polyclonal antibody

BMX Polyclonal Antibody for WB, IF/ICC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IF/ICC, ELISA

Conjugate

Unconjugated

Cat no : 27413-1-AP

Synonyms

BMX, ETK, NTK38, PSCTK2, PSCTK3


☆大好評トライアルサイズ ¥20,000~! >>> 一次抗体特別価格キャンペーン開催中!


Tested Applications

Positive WB detected inHUVEC cells, mouse epididymis tissue
Positive IF/ICC detected inHepG2 cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunofluorescence (IF)/ICCIF/ICC : 1:200-1:800
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

27413-1-AP targets BMX in WB, IF/ICC, ELISA applications and shows reactivity with human, mouse samples.

Tested Reactivity human, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen BMX fusion protein Ag26407 相同性解析による交差性が予測される生物種
Full Name BMX non-receptor tyrosine kinase
Calculated molecular weight 675 aa, 78 kDa
Observed molecular weight70 kDa
GenBank accession numberBC016652
Gene symbol BMX
Gene ID (NCBI) 660
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

BMX (Bone marrow kinase on chromosome X) is a cytosolic tyrosine kinase and a member of the TEC kinase family. BMX is expressed in hematopoietic cells of the myeloid lineage where it participates in the immune response. Moreover, BMX is expressed in several types of cancers and very recently has been shown to mediate the survival and tumorigenicity of glioblastoma cancer stem cells (PMID: 22449076).

Protocols

Product Specific Protocols
WB protocol for BMX antibody 27413-1-APDownload protocol
IF protocol for BMX antibody 27413-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols